Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This investigational cell-based biologic therapy consists of autologous bone marrow-derived mesenchymal stem cells (MSCs) for the treatment of multiple sclerosis. Developed by Dr. Albert Saiz and researchers at the Hospital Clinic of Barcelona and IDIBAPS, the treatment involves the ex vivo expansion of a patient's own MSCs followed by intravenous administration. The therapy is designed to leverage the immunomodulatory and neuroprotective properties of stem cells to treat patients with active relapsing-remitting multiple sclerosis who have not responded to standard treatments. Clinical results from Phase II trials indicate that the cells may modulate T and B cell populations, potentially reducing the cumulative number of gadolinium-enhancing lesions on MRI.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on autologous mesenchymal stem cells (Albert Saiz).